CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net loss	$ (52,196,000)	$ (39,971,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,804,000	5,354,000
Stock-based compensation	12,687,000	7,566,000
Amortization of debt discount and debt issuance costs	3,133,000	2,332,000
Amortization of right-of-use asset	871,000	678,000
Provision for doubtful accounts	79,000	190,000
Provision for excess and obsolete inventory	5,429,000	6,451,000
Deferred income tax benefit		2,000
Beneficial conversion feature from convertible notes		242,000
Loss on disposal of instruments	281,000	478,000
Accretion to contingent consideration		289,000
Loss on extinguishment of debt	1,555,000
Changes in operating assets and liabilities:
Accounts receivable, net	(8,199,000)	(526,000)
Inventories, net	(12,720,000)	(10,751,000)
Prepaid expenses and other current assets	(2,286,000)	263,000
Other assets	(53,000)	127,000
Other long-term assets		(2,864,000)
Accounts payable	4,246,000	3,541,000
Accrued expenses and other	4,561,000	3,313,000
Lease liability	(975,000)	2,528,000
Other long-term liabilities	(3,901,000)	(3,296,000)
Net cash used in operating activities	(39,684,000)	(24,054,000)
Investing activities:
Purchases of property and equipment	(12,868,000)	(10,437,000)
Cash received from sale of assets	27,000
Net cash used in investing activities	(12,841,000)	(10,437,000)
Financing activities:
Proceeds from public offering, net		53,974,000
Proceeds from sale of common stock, net	1,204,000	2,073,000
Borrowings under lines of credit	42,455,000	81,723,000
Repayments under lines of credit	(56,615,000)	(81,161,000)
Principal payments on capital lease obligations	(24,000)	(22,000)
Proceeds from issuance of term debt, net	34,012,000	9,700,000
Principal payments on term loan and notes payable	(24,000)	(3,068,000)
Net cash provided by financing activities	21,008,000	63,219,000
Effect of exchange rate changes on cash	82,000	61,000
Net (decrease) increase in cash	(31,435,000)	28,789,000
Cash at beginning of period, including discontinued operations	47,113,000	29,054,000
Cash at end of period, including discontinued operations	15,678,000	57,843,000
Supplemental disclosure of cash flow information:
Cash paid for interest	4,931,000	4,342,000
Cash paid for income taxes	186,000	102,000
Supplemental disclosure of noncash investing and financing activities:
Common stock warrants issued with term loan draw	2,986,000	13,664,000
Purchases of property and equipment in accounts payable	$ 1,881,000	1,297,000
SafeOp Surgical, Inc.
Supplemental disclosure of noncash investing and financing activities:
Common stock issued for achievement of SafeOp contingent consideration		$ 2,889,000